A cell-based high-throughput screening assay for farnesoid X receptor agonists

Biomedical and Environmental Sciences

Volumn 20, Issue 6, 2007, Pages 465-469

  Zheng, Zhi Hui ^a,c   Lv, Guo Ping ^b   Si, Shu Yi ^a   Dong, Yue Sheng ^c   Zhao, Bao Hua ^b   Zhang, Hua ^c   He, Jian Gong ^c  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b HEBEI NORMAL UNIVERSITY   (China)

^c North China Pharmaceutical Corporation   (China)

Author keywords

Agonist; Chimera; Farnesoid X receptor; High throughput screening

Indexed keywords

ANTILIPEMIC AGENT; CELL RECEPTOR; COMPLEMENTARY DNA; DNA BINDING PROTEIN; FARNESOID X RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; PRIMER DNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CHEMISTRY; DRUG POTENTIATION; GENETIC TRANSFECTION; GENETICS; HUMAN; NUCLEOTIDE SEQUENCE; PLASMID; REPRODUCIBILITY;

ANTILIPEMIC AGENTS; BASE SEQUENCE; CELL LINE; DNA PRIMERS; DNA, COMPLEMENTARY; DNA-BINDING PROTEINS; HUMANS; PLASMIDS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REPRODUCIBILITY OF RESULTS; TRANSCRIPTION FACTORS; TRANSFECTION;

MAMMALIA; SIMIAN VIRUS 40;

EID: 38949174197     PISSN: 08953988     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Kuipers F, Claudel T, Sturm E, et al. (2004). The Farnesoid X Receptor (FXR) as modulator of bile acid metabolism. Rev Endocr Metab Disord 5, 319-326.
2. Tu H, Okamoto A Y, Shan B (2000). FXR, a Bile Acid Receptor and Biological Sensor. TCM 10, 30-35.
3. Lambert G, Amar M J, Guo G, et al. (2003). The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem 278, 2563-2570.
4. Westin S, Heyman R A, Martion R (2005). FXR, a therapeutic target for bile acid and lipid disorders. Mini Rev Med Chem 5, 719-727.
5. Boshop-Bailey D (2004). FXR as a novel therapeutic target for vascular disease. Drug News Perspect 17, 499-504.
6. Doggrell S A (2005). Farnesoid X receptor agonism-a new approach to the treatment of cholesterol gallstone disease. Expert Opin Investig Drugs 14, 535-538.
7. Komichi D, Tazuma S, Nishioka T, et al. (2005). A nuclear receptor ligand down-regulates cytosolic phospholipase A2 expression to reduce bile acid-induced cyclooxygenase 2 activity in cholangiocytes: implications of anticarcinogenic action of farnesoid X receptor agonists. Dig Dis Sei 50, 514-524.
8. Duran-Sandoval D, Cariou B, Fruchart J C, et al. (2005). Potential regulatory role of the farnesoid X receptor in the metabolic syndrome. Biochimie 87, 93-98.
9. Yajima H, Ikeshima E, Shiraki, M (2004). Isohumulones, Bitter Acids Derived from Hops, Activate Both Peroxisome Proliferator-activated Receptor a and y Reduce Insulin Resistance. J Biol Chem 279, 33456-33462.
10. Lehmann J M, Moore L B, Smith-Oliver T A, et al. (1995). An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome roliferators-activated receptor gamma (PPAR gamma). J Biol Chem 270, 12953-12956.
11. Zhang J H, Chung T D, Oldenburg K R (1999). A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4, 67-73.